Research Support in the Field of Cancer

Cancer Research Grants

A major goal for Cancer is to encourage researchers at Linköping University/Region Östergötland to apply for and hold more excellent grants in the cancer area.

For 2024 we announce seed grants with deadline May 15, 2024. The seed grant slot can also include a budget for travel.

This year we also want to encourage academic activities for clinical researchers. A travel grant slot will be open for applications throughout the year 2024.

Instructions for applications to the different grant slots are outlined below.

Seed grant

By this grant slot, we want to recognize and further support excellent cancer research at LiU/RÖ. Application deadline is May 15, 2024.

We encourage novel collaborative projects and constellations as well as continuation of successful projects previously supported by Cancer.

Formal requirements:

Cancer supports projects which involves PIs from two or more research areas within LiU/Region Östergötland. The main applicant (PI) should be employed (40% or more) at Linköping University or Region Östergötland.
Active participation in activities organized by Cancer including in the Cancer Retreat (poster, oral or other activity).
Reports from previous grants from Cancer and progress reports of ongoing projects are requirements for further funding.
Preferably at least one of the applicants should have ongoing excellence grants recognized by LiU: Cancerfonden, EU-kommissionen, EU:s forsknings- och utvecklingsprogram, Formas, Forte, Hjärt-Lungfonden, KA Wallenbergs stiftelse, National Institute of Health, Riksbankens jubileumsfond (RJF), Stiftelsen för Strategisk Forskning, and Vetenskapsrådet. In addition to these, we will also recognize grants from Vinnova and Barncancerfonden.
Nota bene: a grant of excellence will only be considered in one application

The applications will be ranked based on novelty, scientific value and cancer relevance.

For applications, the following material is required:

Title page: name and affiliation of project participants. The main applicant must be a senior scientist at LiU/RÖ. The main applicant should be employed 40% or more at LiU or RÖ.
Project plan: max three pages + max one page of references. Describe the project and aims and how a grant from LiU Cancer will be used to reach these aims. Include a suggested budget and the amount applied for.
Letter of motivation (max 2 pages), including descriptions of:
1. the cancer relevance of your research if not evident from the project plan
2. participation in activities organized by the strategic area Cancer
3. ongoing research activities within the LiU/RÖ Cancer Research network
4. ongoing contracts of excellent funding listed above
If any participant has received previous research support from LiU-Cancer a progress report should be included.
If any participant has received or plans to apply for research support from any other strategic research area at LiU/RÖ this should be reported and a motivation of why Cancer should support the project has to be included.
Short CVs: max 2 pages per co-applicant including list of publications: past 5 years only

Please compile the requested application material into one single pdf file, and send by email to Therese Erwill, therese.erwill@liu.se. Application deadline is May 15, 2024.

Travel grant

By this grant slot we encourage active participation in conferences or shorter research visits for clinical researchers employed by Region Östergötland (RÖ). Application should be submitted at least six weeks before the planned travel.

For attendance to scientific conferences an active participation is required. The abstract submitted to the conference should be included in the application together with a motivation of the added scientific value of attending the conference. A suggested budget should be included. A short CV of max 2 pages including education, current position and employer and a list of recent publications should also be included. A letter of support from the employer should be submitted. Only conferences in the cancer area will be approved.

For support to a shorter research visit to a foreign institution a short project description, max three pages, with background, work plan and significance should be submitted. A suggested budget should be included. A short CV of max 2 pages including education, current position and employer and a list of publications of the past 5 years. A letter of support from the employer should also be submitted. Only research within the cancer area will be approved

Please compile the requested application material into one single pdf file, and send by email to Therese Erwill, therese.erwill@liu.se at least six weeks before the planned travel.

Swedish Cancer Research Meeting 22-23 May 2025

To support participation in the Swedish Cancer Research Meeting 2025 we announce up to 20 travel grants of 7000 SEK, which will cover registration fee, accommodation, and train ticket Linköping-Malmö.

A prerequisite for the grant is an accepted abstract to the conference. For details, please see PDF linked below.

When you have had your abstract accepted, you send it together with the notification that it has been accepted and your CV to Therese Erwill. You can write in the email that you are applying for the travel grant for this particular congress. Deadline for this is 21/3 2025.

Take the chance to meet and mingle with cancer researchers from all over Sweden in Malmö, May 21-22, 2025.

LUCC Register 7th SCRM 18 Nov 2024 (PDF, 357,8 kB)

Previously approved grants

Project grants 2024

Federated learning for efficient and personalized radiotherapy treatment planning
Anders Eklund, Ida Blystad, Neda Haj-Hosseini
500 000 :-

Mapping the activity of gene regulators in a large collection of cancer-derived biopsies discovering the genomic secrets of cancer
Claudio Cantú, Bergthor Björnsson, Per Sandström
250 000 :-

Precision oncology for pediatric brain tumors using artificial intelligence
Neda Haj-Hosseini, Anders Eklund, Peter Lundberg, Ida Blystad, Per Nyman
500 000 :-

Feasibility of Zebrafish Pancreatic Cancer PDX models for evaluating anticancer and tumor-immune effects of novel anti-MYC agents
Lasse Jensen, Linda Bojmar, Bergthor Björnsson, Maria Sunnerhagen
250 000 :-

Development and clinical evaluation of new methods for automized treatment planning of cervical cancer brachytherapy
Åsa Carlsson Tedgren, Torbjörn Larsson, Michael Sandbrog, Björn Morén
455 00 :-

Precision Targeting of Cancer Immortality
Johan Karlsson, Francisca Lottersberger, Daniel Aili
500 000 :-

Multimodal Characterization of the Premetastatic Liver and Extracellular Vesicles in Colorectal Cancer and Development of a Prediction Model for Metastatic Outcome
Linda Bojmar, Erik Lundqvist, Rasmus Magnusson, Chuanwen Fan, Hakon Blomstrand, Constantinos Zambirinis, Per Sandström
250 000 :-

The role of autoimmunity, chronic inflammation, and microenvironment in disease onset and progression of chronic myelomonocytic leukemia (CMML)
Johanna Ungerstedt, Niklas Boknäs
500 000 :-

Computational integrated diagnostics panorama for Hepatocellular carcinoma
Caroline Bivik Stadler, Tomas Bjerner, Bergthor Björnsson, Ignatova Simone, Claes Lundström, Per Sandström, Darren Treanor
500 000 :-

Travel grants 2023

Travel grants ESTRO
Anna Ljusberg
15 000 :-

Travel grant ISMRM
Anna Ljusberg
20 000 :-

Travel grant ISMRM
Yosef Al-Abasse
15 000 :-

Travel grant
Jonatan Eriksson
20 000 :-

Project grants 2023

Exploring the role of PIWIL1 in colorectal cancer
Anita Öst, Rashmi Ranesh
250 000 :-

Nuclear and DNA damage as regulator for extracellular vesicle release and cancer cell dissemination
Anna Fahlgren, Francisca Lottersberger, Lasse Dahl Ejby Jensen
250 000 :-

Discovering how wnt signaling drives metastasis in colorectal cancer: how to distinguish homeostatic from cancer epithelial cells
Claudio Cantù, Elenore von Castelmur, Xiao-Feng Sun
250 000 :-

The role of epi-mutations in childhood cancer predisposition
Colm Nestor, Margareta Nordling, Per Nyman, Ekatarina Kuchinskava
250 000 :-

Functional intrinsic disorder at telomeres in cancer
Francisca Lottersberger, Björn Wallner, Maria Sunnerhagen, Alexandra Ahlner
500 000 :-

Ovarian carcinoma: novel therapeutic strategies
Gabriel Lindahl, Stig Linder, Martina Bazzaro
150 000 :-

Tumörvirus-(re)aktivering, defekt interferon/STING-signalväg: Riskfaktorer för utveckling av non-Hodgkin lymfom/Kronisk lymfatisk leukemi
Ioannis Spyrous, Erini Apostolou, Love Tätting, Anders Rosén
150 000 :-

Specific delivery of radio sensitizing nanoprobes to EGFR overexpressing head and neck cancer cells: Nanoprobes equipped with Cetuximab for targeted Imaging
Kajsa Uvdal, Karin Roberg
150 000 :-

Hepatic metabolism as a pro- or anti-metastatic regulator?
Linda Bojmar, Elin Nyman, Gunnar Cedersund, Per Sandström, Bergthor Björnsson, Constantions Zambirinis
250 000 :-

Mechanisms of Tumorigenesis and Genetic Variant-Specific “Drugability” of Pheochromocytoma
Oliver Gimm, Peter Söderkvist
150 000 :-

Inhibition of PI4KB activity as a potential treatment strategy for Multiple Myeloma
Padraig D´arcy, Love Tätting, Hareth Nahi
500 000 :-

Liquid biopsy for follow up and treatment monitoring of glioma patients
Peter Söderkvist, Malgorzata Lysiak, Malgorzata Trybula, Peter Milos
250 000 :-

Targeting colorectal cancer metastasis by exploring the FOXQ1-associated transcriptional complex
Stefan Koch, Xiao-Feng Sun
250 000 :-

Unraveling the Genetic Architecture of Circulating Plasma Proteome for Colorectal Cancer Risk Assessment and Patient Stratification
Wen Zhong, Margareta Nordling
150 000 :-

Improving Chemotherapy and Radiotherapy Response by Synergistic Combination with Statins in Subgroups of Colorectal Cancer Patients
Xiao-Feng Sun, Annica Knutsen, Angeliki Kotti, Surajit Pathak, Wen Zhong
100 000 :-

Development of new methods for automized treatment planning of cervical cancer brachytherapy
Åsa Carlsson Tedgren, Torbjörn Larsson, Michael Sandborg, Björn Morén
250 000 :-

Project grants 2022

Infektioner och autoimmunitet riskfaktorer för non-Hodgkin B-cellslymfom
Giannis Spyrou, Anders Rosén, Eirini Apostolou, Kourosh Lotfi
150 000 :-

Micromechanical characterization of the dynamic breast cancer microenvironment
Daniel Aili, Francisca Lottersberger, Charlotta Dabrosin
500 000 :-

Selective targeting of protein degradation to combat cancer – a continued translational approach
Pádraig D'Arcy, Maria Sunnerhagen, Alina Castell, Alexandra Ahlner
500 000 :-

Targeting the DNA Damage Repair and HRAS signalling pathways for the treatment of pheochromocytomas and paragangliomas
Oliver Gimm, Peter Söderkvist, Mouna Tababi, Hugo Rossitti
250 000 :-

Brain tumor diagnosis using advanced image analytics
Neda Haj-Hosseini, Anders Eklund, Evren Özarslan, Peter Lundberg, Ida Blystad, Per Nyman
500 000 :-

Computational integrated diagnostics panorama for Hepatocellular carcinoma
Claes Lundström, Tomas Bjerner, Darren Treanor, Per Sandström, Bergthor Björnsson, Caroline Bivik Stadler
500 000 :-

OncoABIS: Mapping genetic and epigenetic predisposition to cancer
Colm Nestor, Johnny Ludvigsson, Per Nyman
500 000 :-

Heredity, genetics and biomarkers – possibilities of improved precision medicine in colorectal cancer
Margareta Nordling, Peter Söderkvist
250 000 :-

Statin sensitized colorectal cancer to radiotherapy
Xiao-Feng Sun, Lasse Jensen, Hans Olsson, Tuan Pham
200 000 :-

Liquid biopsy and follow up study of glioma tumors - Scientific environment and co-applicants
Peter Söderkvist, Malgorzata Lysiak, Annika Malmström, Martin Hallbeck, Peter Milos
500 000 :-

Project grants 2021

Mapping the WNT signalling transcriptional complex in colorectal cancer ‐ uncovering how to distinguish normal from cancer cells
Claudio Cantù, Eleonore von Castelmur, Xiao‐Feng Sun
500 000 :-

Clinical validation of a novel mathematical optimization tool for automated post‐adjustment of brachytherapy treatment plans – continuation project
Åsa Carlsson Tedgren, Michael Sandbord, Torbjörn Larsson
470 000 :-

Selective targeting of protein degradation to combat cancer ‐ a translational approach
Pádraig D'Arcy, Maria Sunnerhagen, Björn Wallner, Linda Penn
500 000 :-

Brain tumor classification using advanced image analytics
Anders Eklund, Neda Haj‐Hosseini, Evren Özarslan, Ida Blystad
500 000 :-

Exosomes to detect somatic mutations in pheochromocytoma and paraganglioma in order to facilitate mutation‐specific drug treatment
Oliver Gimm, Peter Söderkvist, Mouna Tabebi
200 000 :-

Ovarian cancer: prediction of therapy outcome using a zebrafish PDX model and analyses of biomarkers
Gabriel Lindahl, Lasse Jensen, Stig Linder
500 000 :-

Mechanical factors and genome stability as factors in metastatic progression
Francisca Lottersberger, Anna Fahlgren, Lasse Jensen
500 000 :-

Improved treatment of glioma using novel quantitative magnetic resonance imaging
Peter Lundberg, Anders Tisell, Ida Blystad, Annika Malmström, Maria Kristoffersen Wiberg, Munilla Mudasi, Per Nyman, Angie Landgren, Anna Ljusberg, Ulf Samuelsson
500 000 :-

TET2 as a novel therapeutic target in T‐cell acute lymphoblastic leukemia
Colm Nestor, Mika Gustafsson, Maike Bensberg
500 000 :-

Improving radiotherapy response in rectal cancers
Xiao‐Feng Sun, Lasse Jensen, Hans Olsson, Xuqin Xie, Chuanwen Fan, Bin Luo
200 000 :-

Tumor educated platelets and methylome in diagnosis, prognosis, treatment prediction and progression of brain tumors
Peter Söderkvist, Malgorzata Lysiak, Martin Hallbeck, Annika Malmström, Peter Milos, Anders Tisell
500 000 :-

Specific delivery of radio sensitizing nanoprobes to EGFR overexpressing head and neck cancer cells
Kajsa Uvdal, Karin Roberg
200 000 :-

Project grants 2020 + extended grants

Evaluation of SDHB gene and identification of potentially therapeutic drugs for pheochromocytoma and paraganglioma
Oliver Gimm, Peter Söderkvist, Mouna Tabebi
200 000 :- + 170 000 :-

Identification of genetic and epigenetic biomarkers for predicting therapy response in head and neck cancer
Karin Roberg, Carlos Guerrero Bosagna
300 000 :-

SAMD9(L) and telomeres in cancer and bone marrow failure
Jörg Cammenga, Francisca Lottersberger, Björn Wallner
500 000 :-

Mathematical Oncology Mathematical Contribution to Brain Cancer research
George Baravdish, Jonas Unger, Tomas Johansson
150 000 :-

An explorative clinical study of low dose acetylsalicylic acid for reduction of local inflammation and breast density – continuation grant
Charlotta Dabrosin, Peter Lundberg, Maria Kristoffersen Wiberg, Pantelis Gialias
450 000 :- + 382 000 :-

The role of sex differences and fusion genes for development and treatment of glioblastoma
Peter Söderkvist, Malgorzata Lysiak, Martin Hallbeck, Annika Malmström, Peter Milos
200 000 :- + 170 000 :-

Clinical validation of a novel mathematical optimization tool for automated post-adjustment of brachytherapy treatment plans
Åsa Carlsson Tedgren, Michael Sandborg, Torbjörn Larsson
450 000 :-

p53 Reactivation by APR-246 to Enhance Response of Preoperative Radiotherapy (pRT) in Rectal Cancer Patients
Xiao-Feng Sun, Lasse Jensen, Xuqin Xie, Chuanwen Fan
200 000 :- + 170 000 :-

USP14 and UCHL5 Deubiquitinases (DUBs) for cancer therapy – a case-driven investigation empowering cancer drug screening for LiU Cancer researchers
Padraig D´arcy, Maria Sunnerhagen, Alexandra Ahlner, Dhananjay Singh
500 000 :-

Brain tumor classification using advanced image analytics
Anders Eklund, Neda Haj Hosseini, Evren Özarslan, Ida Blystad, Peter Milos, Martin Hallbeck
300 000 :- + 255 000 :-

Sex-bias in paediatric T-cell acute lymphoblastic leukemia; towards precision medicine
Colm Nestor, Mika Gustafsson
500 000 :- + 427 000 :-

Infections and autoimmune risk factors for B-cell non-Hodgkin lymphoma
Anders Rosén, Giannis Spyrou, Eirini Apostoulo, Björn Ingelsson, Kourosh Lotfi
200 000 :- + 170 000 :-

Project grants 2019

Mapping the molecular architecture of the WNT/B-catenin transcriptional complex in colorectal cancer
Claudio Cantù, Eleonore von Castelmur
400 000:-

Optical Biopsy for Low Grade Brain Tumour Diagnostics - First steps towards a Raman spectroscopy system for clinical use
Karin Wårdell, Neda Haj-Hosseini, Tuan Pham, Johan Richter, Peter Milos, Jan Hillman, Martin Hallbeck
400 000:-

New frontiers in precision cancer medicine: Evaluating drug efficacy in ovarian cancer using zebrafish PDX models
Lasse Jensen, Charlotta Dabrosin, Stig Linder, Preben Kjölhede
400 000:-

Sexual dimorphism in glioma
Malgorzata Lysiak, Peter Söderkvist, Martin Hallbeck, Annika Malmström, Peter Milos
400 000:-

Project grants 2018

An explorative clinical study of low dose acetylsalicylic acid for reduction of local inflammation and breast density
Charlotta Dabrosin, Peter Lundberg, Maria Kristoffersen Wiberg, Pantelis Gialias
500 000:-

Role of REELIN and LRP8 in adrenal cortex tumors associated with hypertension
Oliver Gimm, Peter Söderkvist
300 000:-

Dissecting the function of DNA de-methylation in T-cell malignancies
Colm Nestor, Henrik Green, Olov Ekwall
500 000:-

Specific cancer drug delivery with tailormade nanoprobes - identification of tumor biomarkers that are useable for target therapy in head and neck cancer
Karin Roberg, Luiza Hernandez, Kajsa Uvdal
300 000:-

RhoB in relation to chemotherapy and radiotherapy in vitro and in vivo
Xiao-Feng Sun, Maria Kopsida, Na Liu, Lasse Jensen
100 000:-

Molecular and clinical refinement of proteasome deubiquitinase (DUB) inhibitors for cancer therapy
Maria Sunnerhagen, Alexandra Ahlner, Padraig D'Arcy, Eleonore von Castelmur, Stig Linder
400 000:-

Distinguishing pseudoprogression from tumour progression in glioblastoma patients treated with chemo and radiation therapy
Anders Tisell, Maria Kristoffersen Wiberg, Ida Blystad, Peter Lundberg, Annika Malmström, Munila Mudaisi
200 000:-

Optical biopsy for real-time brain tumour diagnostics during stereotactic neurosurgery & pilot study with raman spectroscopy
Karin Wårdell, Neda Haj-Hosseini, Johan Richter, Peter Milos, Martin Hallbeck
500 000:-

Project grants 2017

The role and mechanism of TP73 on colorectal cancer stem cells and endothelial differentiation
Xiao-Feng Sun, Lasse Jensen
350 000:-

Low dose acetylsalicylic acid for reduction of breast density and inflammation
Peter Lundberg, Charlotta Dabrosin
500 000:-

Genetic alterations involved in glioma
Peter Söderkvist, Annika Malmström, Peter Milos
300 000:-

Validation of new susceptibility genes and identification of potentially therapeutic drugs for pheochromocytomas
Oliver Gimm, Peter Söderkvist
300 000:-

Optical biopsy for real-time brain tumour diagnostic during stereotactic neurosurgery
Karin Wårdell, Neda Haj Hosseini, Johan Richter, Peter Milos, Martin Hallbeck
500 000:-

Improving proteasome deubiquitinase (DUB) inhibitors for cancer therapy
Maria Sunnerhagen, Stig Linder
350 000:-

Project grants 2016

Deciphering the AEG-1/NF-κB and TGFb/SMAD7 Signalling Pathways in Radiation Treated Colorectal Cancer by Detecting Bioluminescence with Organic Photodetectors
Xiao-Feng Sun, Fengling Zhang, Wing Cheung Mak
300 000:-

Genetic alterations involved in malignant transformation of low-grade glioma
Peter Söderkvist, Annika Malmström, Peter Milos
300 000:-

Dynamic molecular refinement of novel cancer drugs for multiple myeloma that targets the ubiquitin-proteasome system
Maria Sunnerhagen, Stig Linder
300 000:-

Breast Cancer Risk Assessment: Evaluation of a Comprehensive Magnetic Resonance-Based Protocol
Magnus Borga, Peter Lundberg, Charlotta Dabrosin, Anna Rzepecka, Johan Kihlberg
300 000:-

Optical Biopsy for Real-time Brain Tumour Diagnostics during Stereotactic Neurosurgery
Karin Wårdell, Neda-Haj-Hosseini, Johan Richter, Peter Milos, Martin Hallbeck
300 000:-

ARID1A as a therapeutic target in lymphoid and myeloid hematologic malignancies
Jörg Cammenga, Mikael Sigvardsson
300 000:-

Dissecting the function of DNA de-methylation in T-cell malignancies
Colm Nestor, Henrik Green, Hartmut Vogt
300 000:-

Project grants, autumn 2014

Uppstartsanslag HT 2014
Dessa anslag är inriktade mot stöd för nya samarbetsprojekt i konstellationer som inte tidigare fått stöd från LiU Cancer, och som involverar forskningsledare (docent eller högre) från två eller flera forskningsområden inom LiU. Ansökningarna kommer att rankas baserat på nyhetsvärde, vetenskaplig kvalitet och cancerrelevans.

Pharmacogenetic studies on ovarian cancer
Henrik Gréen, Elisabeth Åvall Lundqvist
200 000:-

Comprehensive structural and functional characterization of FLT3 mutations for anti-leukemic targeted strategy
Jan-Ingvar Jönsson, Patrik Lundström, Amanda Nordigården, Maria Sunnerhagen
200 000:-

L-myc an oncogene vs immune regulator
Marie Larsson, Maria Sunnerhagen, Linda Penn
200 000:-

Spectroscopic imaging techniques to detect oxygen concentration and oxidative stress
Mikael Lindgren, Håkan Gustafsson, Lasse Jensen, Anders Rosén, Stig Linder, Karin Roberg
200 000:-

Medfinansiering av excellenta anslag HT 2014
Med detta anslag vill vi erkänna och ge möjlighet till ökat stöd för excellent cancerforskning vid LiU. Aktivt deltagande (poster, muntlig presentation) vid LiU Cancers retreat 2014 krävs för att komma ifråga för detta anslag. Pågående excellenta anslagsgivare som erkänns av LiU och i denna utlysning är: Cancerfonden, EU-kommissionen, EU:s forsknings- och utvecklingsprogram, Formas, Forte, Hjärt-Lungfonden, KA Wallenbergs stiftelse, National Institute of Health, Riksbankens jubileumsfond (RJF), Stiftelsen för Strategisk Forskning, och Vetenskapsrådet. Förutom dessa räknar vi också in Vinnova och Barncancerfonden i denna utlysning. Ansökningarna kommer att utvärderas baserat på relevansen för cancerforskning.

Development of novel cancer therapeutics
Stig Linder
300 000:-

Growth regulatory pathways in breast cancer and targeted therapies
Olle Stål
200 000:-

Identification of biomarker associated with early diagnosis, therapy response and prognosis in colorectal cancer patients
Xiao-Feng Sun
200 000:-

Project grants, spring 2014

Whole-transcriptome RNA-seq profiling and genetic network of human mucinous and non-mucinous colorectal adenocarcinoma
Xiao-Feng Sun, Surajit Pathak, Patrik Waldmann, Birgitta Holmlund, Gunnar Arbman
300 000:-

Molecular and clinical studies of primary brain tumors
Peter Söderkvist, Henrik Gréen, Marie Stenmark Askmalm
300 000:-

Personalised treatment of acute lymphoblastic leukaemia - pharmacogenetic and biophysical studies of thiopurine methyltransferase
Malin Lindqvist Appell, Peter Söderkvist, Patrik Lundström, Lars-Göran Mårtensson, Anna Lindblom
300 000:-

Identification and validation of antileukemic therapeutic targets by single cell CyTOF mass cytometry
Jan-Ingvar Jönsson, Henrik Gréen, Kourosh Lotfi
300 000:-

Seed grants, spring 2014

Breast cancer risk assessment: Development of a comprehensive magnetic resonance-based protocol
Magnus Borga, Anna Rzepecka, Johan Kihlberg, Peter Lundberg
150 000:-

Optical techniques for lymph node mapping during Surgery
Neda Haj-Hosseini, Ivan Shabo, Karin Wårdell, Oliver Gimm
90 000:-

Project grants 2012

Transcriptional activation in aggressive lymphoma - a multidisciplinary approach towards identifying novel therapeutic opportunities
Susana Cristobal, Mikael Sigvardsson, Maria Sunnerhagen, Malin Larsson
450 000:-

Accurate info about the tumour - under the surgeon's eyes
Örjan Smedby, Karin Wårdell, Sandro Rossitti
450 000:-

Regulation of the microenvironment in breast cancer - revealing mechanisms for breast cancer progression using novel in vivo techniques
Charlotta Dabrosin, Håkan Gustafsson, Lasse Jensen
450 000:-

Personalised treatment of acute lymphoblastic leukaemia - pharmacogenetic and biophysical studies of thiopurine methyltransferase
Malin Lindqvist Appel, Peter Söderkvist, Lars-Göran Mårtensson, Patrik Lundström, Kourosh Lotfi
450 000:-

Redox proteomics of receptor-signaling in chronic lymphocytic leukema (CLL)
Anders Rosén, Giannis Spyrou, Kourosh Lotfi
450 000:-

Quantitative imaging in tumour oxygenation with electron paramagnetic resonance imaging (EPRI)
Håkan Gustafsson, Alexandru Dasu, Karin Roberg
300 000:-

Towards a personalized anti‐leukemia strategy of prognosis and therapeutic pre‐testing
Jan-Ingvar Jönsson, Henrik Green, Kourosh Lotfi
300 000:-

Early detection of cardiac effects induced by treatment for breast cancer
Alexandru Dasu, Jan Engvall, Olle Stål
300 000:-

Clinical relevance of mTOR and its effectors S6K1, S6K2, and 4EBP1 in breast cancer ‐ S6K2 as a new potential treatment target
Patrik Lundström, Anna-Lotta Hallbeck, Olle Stål
300 000:-

Genetic alterations in sporadic pheochromocytomas
Oliver Gimm, Peter Söderkvist
300 000:-

Molecular and clinical studies of chemoresistance and epigenetic susceptibility to temozolomide treatment in primary brain tumors
Peter Söderkvist, Marie Stenmark Askmalm, Henrik Green
300 000:-

Seed grants 2011

Multifunctional Nanoprobes for Cancer Diagnosis, In vivo Imaging, and Drug Delivery
Kajsa Uvdal, Oliver Gimm, Caroline Skoglund, Xuanjun Zhang
75 000 SEK

Structural and biophysical characterisation of the oncoprotein S6K2
Patrik Lundström, Olle Stål
75 000 SEK

Quantitative oximetry with electron paramagnetic resonance imaging (EPRI)
Håkan Gustafsson, Alexandru Dasu
75 000 SEK

Does antibiotics affect the TPMT enzyme activity in leukemic cells?
Lars-Göran Mårtensson, Malin Lindqvist
75 000 SEK

The danger of sunbathing; detection of radicals in the skin after UV-irradiation using electron paramagnetic resonance
Karin Öllinger, Håkan Gustafsson, Inger Rosdahl, Petra Wäster, Hanna Appelqvist
50 000 SEK

Novel imaging agents and anti-cancer drugs: towards quantitative molecular imaging and target drug delivery
Peter Nilsson, Marek Los, Jeff Mason
50 000 SEK

Pharmacogenetic studies of oxaliplatin induced neurotoxicity
Susanne Börjesson, Henrik Gréen
50 000 SEK

Graphical user interface to connect brachytherapy optimization research code with clinical applications
Åsa Carlsson Tedgren, Torbjörn Larsson
50 000 SEK